Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Stoichiometric Analyses of Soluble CD4 to Native-like HIV-1 Envelope by Single-Molecule Fluorescence Spectroscopy.

Agrawal P, DeVico AL, Foulke JS Jr, Lewis GK, Pazgier M, Ray K.

Cell Rep. 2019 Oct 1;29(1):176-186.e4. doi: 10.1016/j.celrep.2019.08.074.

2.

Concurrent Exposure of Neutralizing and Non-neutralizing Epitopes on a Single HIV-1 Envelope Structure.

Ray K, Mengistu M, Orlandi C, Pazgier M, Lewis GK, DeVico AL.

Front Immunol. 2019 Jul 5;10:1512. doi: 10.3389/fimmu.2019.01512. eCollection 2019.

3.

Broadly Neutralizing Antibodies against HIV: Back to Blood.

Dashti A, DeVico AL, Lewis GK, Sajadi MM.

Trends Mol Med. 2019 Mar;25(3):228-240. doi: 10.1016/j.molmed.2019.01.007. Epub 2019 Feb 18. Review.

PMID:
30792120
4.

Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response.

Sui Y, Lewis GK, Wang Y, Berckmueller K, Frey B, Dzutsev A, Vargas-Inchaustegui D, Mohanram V, Musich T, Shen X, DeVico A, Fouts T, Venzon D, Kirk J, Waters RC, Talton J, Klinman D, Clements J, Tomaras GD, Franchini G, Robert-Guroff M, Trinchieri G, Gallo RC, Berzofsky JA.

J Clin Invest. 2019 Mar 1;129(3):1314-1328. doi: 10.1172/JCI122110. Epub 2019 Feb 18.

5.

Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses.

Sajadi MM, Dashti A, Rikhtegaran Tehrani Z, Tolbert WD, Seaman MS, Ouyang X, Gohain N, Pazgier M, Kim D, Cavet G, Yared J, Redfield RR, Lewis GK, DeVico AL.

Cell. 2018 Jun 14;173(7):1783-1795.e14. doi: 10.1016/j.cell.2018.03.061. Epub 2018 May 3.

6.

Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell-mediated cytotoxicity assay.

Pollara J, Orlandi C, Beck C, Edwards RW, Hu Y, Liu S, Wang S, Koup RA, Denny TN, Lu S, Tomaras GD, DeVico A, Lewis GK, Ferrari G.

Cytometry A. 2018 Apr;93(4):436-447. doi: 10.1002/cyto.a.23348. Epub 2018 Mar 2.

7.

Patterns of conserved gp120 epitope presentation on attached HIV-1 virions.

Mengistu M, Tang AH, Foulke JS Jr, Blanpied TA, Gonzalez MW, Spouge JL, Gallo RC, Lewis GK, DeVico AL.

Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9893-E9902. doi: 10.1073/pnas.1705074114. Epub 2017 Oct 30.

8.

Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a "stochastic" process.

Gonzalez M, DeVico AL, Spouge JL.

Retrovirology. 2017 Feb 24;14(1):13. doi: 10.1186/s12977-016-0326-1.

9.

Survivors Remorse: antibody-mediated protection against HIV-1.

Lewis GK, Pazgier M, DeVico AL.

Immunol Rev. 2017 Jan;275(1):271-284. doi: 10.1111/imr.12510. Review.

10.

Human Th17 Cells Lack HIV-Inhibitory RNases and Are Highly Permissive to Productive HIV Infection.

Christensen-Quick A, Lafferty M, Sun L, Marchionni L, DeVico A, Garzino-Demo A.

J Virol. 2016 Aug 12;90(17):7833-47. doi: 10.1128/JVI.02869-15. Print 2016 Sep 1.

11.

An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques.

Schwartz JA, Prado I, Misamore J, Weiss D, Francis J, Pal R, Huaman M, Cristillo A, Lewis GK, Gallo RC, DeVico AL, Fouts TR.

Clin Vaccine Immunol. 2016 Jul 5;23(7):618-27. doi: 10.1128/CVI.00115-16. Print 2016 Jul.

12.

Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 Region.

Tolbert WD, Gohain N, Veillette M, Chapleau JP, Orlandi C, Visciano ML, Ebadi M, DeVico AL, Fouts TR, Finzi A, Lewis GK, Pazgier M.

Structure. 2016 May 3;24(5):697-709. doi: 10.1016/j.str.2016.03.005. Epub 2016 Mar 31.

13.

Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins.

Khattar SK, DeVico AL, LaBranche CC, Panda A, Montefiori DC, Samal SK.

J Virol. 2015 Nov 18;90(3):1682-6. doi: 10.1128/JVI.02847-15. Print 2016 Feb 1.

14.

Modulating the durability of anti-HIV gp120 antibody responses after vaccination: a comment on Wilson & Karp (2015).

DeVico AL, Lewis GK, Gallo RC.

Philos Trans R Soc Lond B Biol Sci. 2015 Nov 5;370(1681). pii: 20150199. doi: 10.1098/rstb.2015.0199. No abstract available.

15.
16.

Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.

Latinovic OS, Zhang J, Tagaya Y, DeVico AL, Fouts TR, Schneider K, Lakowicz JR, Heredia A, Redfield RR.

Curr HIV Res. 2016;14(1):24-36.

PMID:
26354735
17.

λ Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies.

Sajadi MM, Farshidpour M, Brown EP, Ouyang X, Seaman MS, Pazgier M, Ackerman ME, Robinson H, Tomaras G, Parsons MS, Charurat M, DeVico AL, Redfield RR, Lewis GK.

J Infect Dis. 2016 Jan 1;213(1):156-64. doi: 10.1093/infdis/jiv448. Epub 2015 Sep 7.

18.

Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1.

Gohain N, Tolbert WD, Acharya P, Yu L, Liu T, Zhao P, Orlandi C, Visciano ML, Kamin-Lewis R, Sajadi MM, Martin L, Robinson JE, Kwong PD, DeVico AL, Ray K, Lewis GK, Pazgier M.

J Virol. 2015 Sep;89(17):8840-54. doi: 10.1128/JVI.01232-15. Epub 2015 Jun 17.

19.

Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates.

Shen X, Duffy R, Howington R, Cope A, Sadagopal S, Park H, Pal R, Kwa S, Ding S, Yang OO, Fouda GG, Le Grand R, Bolton D, Esteban M, Phogat S, Roederer M, Amara RR, Picker LJ, Seder RA, McElrath MJ, Barnett S, Permar SR, Shattock R, DeVico AL, Felber BK, Pavlakis GN, Pantaleo G, Korber BT, Montefiori DC, Tomaras GD.

J Virol. 2015 Aug;89(16):8643-50. doi: 10.1128/JVI.03635-14. Epub 2015 May 27.

20.

Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells.

Mengistu M, Ray K, Lewis GK, DeVico AL.

PLoS Pathog. 2015 Mar 25;11(3):e1004772. doi: 10.1371/journal.ppat.1004772. eCollection 2015 Mar. Erratum in: PLoS Pathog. 2015 Jun;11(6):e1004990.

21.

Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.

Fouts TR, Bagley K, Prado IJ, Bobb KL, Schwartz JA, Xu R, Zagursky RJ, Egan MA, Eldridge JH, LaBranche CC, Montefiori DC, Le Buanec H, Zagury D, Pal R, Pavlakis GN, Felber BK, Franchini G, Gordon S, Vaccari M, Lewis GK, DeVico AL, Gallo RC.

Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E992-9. doi: 10.1073/pnas.1423669112. Epub 2015 Feb 13. Erratum in: Proc Natl Acad Sci U S A. 2015 May 5;112(18):E2413.

22.
23.

HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques.

Thomas MA, Tuero I, Demberg T, Vargas-Inchaustegui DA, Musich T, Xiao P, Venzon D, LaBranche C, Montefiori DC, DiPasquale J, Reed SG, DeVico A, Fouts T, Lewis GK, Gallo RC, Robert-Guroff M.

Virology. 2014 Dec;471-473:81-92. doi: 10.1016/j.virol.2014.10.001. Epub 2014 Oct 28.

24.

Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.

Lewis GK, DeVico AL, Gallo RC.

Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15614-21. doi: 10.1073/pnas.1413550111. Epub 2014 Oct 27. Review.

25.

Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection.

Acharya P, Tolbert WD, Gohain N, Wu X, Yu L, Liu T, Huang W, Huang CC, Kwon YD, Louder RK, Luongo TS, McLellan JS, Pancera M, Yang Y, Zhang B, Flinko R, Foulke JS Jr, Sajadi MM, Kamin-Lewis R, Robinson JE, Martin L, Kwong PD, Guan Y, DeVico AL, Lewis GK, Pazgier M.

J Virol. 2014 Nov;88(21):12895-906. doi: 10.1128/JVI.02194-14. Epub 2014 Aug 27.

26.

Epitope target structures of Fc-mediated effector function during HIV-1 acquisition.

Lewis GK, Guan Y, Kamin-Lewis R, Sajadi M, Pazgier M, Devico AL.

Curr Opin HIV AIDS. 2014 May;9(3):263-70. doi: 10.1097/COH.0000000000000055. Review.

27.

Antigenic properties of the HIV envelope on virions in solution.

Ray K, Mengistu M, Yu L, Lewis GK, Lakowicz JR, DeVico AL.

J Virol. 2014 Feb;88(3):1795-808. doi: 10.1128/JVI.03048-13. Epub 2013 Nov 27. Erratum in: J Virol. 2014 May;88(10):5901. Yu, Lei [added].

28.

Editorial: Fc receptor-mediated effector functions in the humoral control of HIV-1 infection.

DeVico A.

Curr HIV Res. 2013 Jul;11(5):343-4. No abstract available.

PMID:
24191941
29.

Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding.

Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, Flinko R, Lovo E, Wu X, Robinson JE, Seaman MS, Fouts TR, Gallo RC, DeVico AL, Lewis GK.

Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):E69-78. doi: 10.1073/pnas.1217609110. Epub 2012 Dec 13.

30.

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.

Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Tsao CY, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim JH, Michael NL, Tomaras GD, Montefiori DC, Lewis GK, DeVico A, Evans DT, Ferrari G, Liao HX, Haynes BF.

J Virol. 2012 Nov;86(21):11521-32. doi: 10.1128/JVI.01023-12. Epub 2012 Aug 15.

31.

Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH.

N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.

32.

Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of β chemokines and RNases.

Cocchi F, DeVico AL, Lu W, Popovic M, Latinovic O, Sajadi MM, Redfield RR, Lafferty MK, Galli M, Garzino-Demo A, Gallo RC.

Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5411-6. doi: 10.1073/pnas.1202240109. Epub 2012 Mar 19.

33.

Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.

Sajadi MM, Lewis GK, Seaman MS, Guan Y, Redfield RR, DeVico AL.

J Virol. 2012 May;86(9):5014-25. doi: 10.1128/JVI.06547-11. Epub 2012 Feb 29.

34.

Identification and characterization of an immunogenic hybrid epitope formed by both HIV gp120 and human CD4 proteins.

Lewis GK, Fouts TR, Ibrahim S, Taylor BM, Salkar R, Guan Y, Kamin-Lewis R, Robinson JE, Devico AL.

J Virol. 2011 Dec;85(24):13097-104. doi: 10.1128/JVI.05072-11. Epub 2011 Oct 12. Erratum in: J Virol. 2012 May;86(9):5410. Robinson, James E [added].

35.

Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs.

Khattar SK, Samal S, Devico AL, Collins PL, Samal SK.

J Virol. 2011 Oct;85(20):10529-41. doi: 10.1128/JVI.05050-11. Epub 2011 Aug 17.

36.

Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.

Latinovic O, Le N, Reitz M, Pal R, DeVico A, Foulke JS, Redfield RR, Heredia A.

AIDS. 2011 Jun 1;25(9):1232-5. doi: 10.1097/QAD.0b013e3283471edb.

37.

Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity.

Sajadi MM, Guan Y, DeVico AL, Seaman MS, Hossain M, Lewis GK, Redfield RR.

J Acquir Immune Defic Syndr. 2011 May 1;57(1):9-15. doi: 10.1097/QAI.0b013e3182100c1b.

38.

Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection.

Guan Y, Sajadi MM, Kamin-Lewis R, Fouts TR, Dimitrov A, Zhang Z, Redfield RR, DeVico AL, Gallo RC, Lewis GK.

Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3952-7. doi: 10.1073/pnas.0813392106. Epub 2009 Feb 18.

39.

Self-protection of individual CD4+ T cells against R5 HIV-1 infection by the synthesis of anti-viral CCR5 ligands.

Guan Y, Abdelwahab S, Kamin-Lewis R, DeVico AL, Lewis GK.

PLoS One. 2008;3(10):e3481. doi: 10.1371/journal.pone.0003481. Epub 2008 Oct 22.

40.

An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence.

Taylor BM, Foulke JS, Flinko R, Heredia A, DeVico A, Reitz M.

J Virol. 2008 Jun;82(11):5460-71. doi: 10.1128/JVI.01049-07. Epub 2008 Mar 19.

41.

CD4-induced epitopes in the HIV envelope glycoprotein, gp120.

DeVico AL.

Curr HIV Res. 2007 Nov;5(6):561-71. Review.

PMID:
18045112
42.

Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens.

DeVico A, Fouts T, Lewis GK, Gallo RC, Godfrey K, Charurat M, Harris I, Galmin L, Pal R.

Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17477-82. Epub 2007 Oct 23.

43.

Production of the HIV-suppressive chemokines CCL3/MIP-1alpha and CCL22/MDC is associated with more effective antiretroviral therapy in HIV-infected children.

Lambert JS, Machado ES, Watson DC, Sill AM, Lim JK, Charurat M, Cunha SM, Afonso AO, Oliviera RH, Tanuri A, DeVico AL.

Pediatr Infect Dis J. 2007 Oct;26(10):935-44.

PMID:
17901800
44.

Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment.

Gilliam BL, Heredia A, Devico A, Le N, Bamba D, Bryant JL, Pauza CD, Redfield RR.

AIDS. 2007 Oct 1;21(15):2108-10.

PMID:
17885304
45.

CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1.

Heredia A, Gilliam B, DeVico A, Le N, Bamba D, Flinko R, Lewis G, Gallo RC, Redfield RR.

AIDS. 2007 Jun 19;21(10):1317-22.

PMID:
17545708
46.

Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.

Heredia A, Gilliam B, Latinovic O, Le N, Bamba D, Devico A, Melikyan GB, Gallo RC, Redfield RR.

Antimicrob Agents Chemother. 2007 Jul;51(7):2489-96. Epub 2007 May 7.

47.

Evaluation of -2 RANTES vaginal microbicide formulations in a nonhuman primate simian/human immunodeficiency virus (SHIV) challenge model.

Kish-Catalone T, Pal R, Parrish J, Rose N, Hocker L, Hudacik L, Reitz M, Gallo R, Devico A.

AIDS Res Hum Retroviruses. 2007 Jan;23(1):33-42.

PMID:
17263630
48.

N-terminal proteolytic processing by cathepsin G converts RANTES/CCL5 and related analogs into a truncated 4-68 variant.

Lim JK, Lu W, Hartley O, DeVico AL.

J Leukoc Biol. 2006 Dec;80(6):1395-404. Epub 2006 Sep 8.

PMID:
16963625
49.

An immunoglobulin fusion protein based on the gp120-CD4 receptor complex potently inhibits human immunodeficiency virus type 1 in vitro.

Vu JR, Fouts T, Bobb K, Burns J, McDermott B, Israel DI, Godfrey K, DeVico A.

AIDS Res Hum Retroviruses. 2006 Jun;22(6):477-90.

PMID:
16796521
50.

Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5.

Kish-Catalone TM, Lu W, Gallo RC, DeVico AL.

Antimicrob Agents Chemother. 2006 Apr;50(4):1497-509.

Supplemental Content

Loading ...
Support Center